Clinical trials to test the new drugs in patients should begin as early as 2015.
Existing drugs target faulty versions of a protein called BRAF which drives about half of all melanomas, but while initially very effective, the cancers almost always become resistant to treatment within a year.
The new drugs - called panRAF inhibitors - could be effective in patients with melanoma who have developed resistance to BRAF inhibitors.
The new study was funded by the Wellcome Trust and Cancer Research UK, and jointly led by scientists at The Institute of Cancer Research, London, and the Cancer Research UK Manchester Institute.
It is published in the prestigious journal Cancer Cell today (Thursday).
The researchers showed that the new drugs - provisionally named CCT196969 and CCT241161 - stopped the growth of BRAF-driven melanomas, including those that had stopped responding to currently available BRAF-targeted drugs.
In addition, the new drugs halted tumour growth in cancers in which BRAF-targeted drugs had never worked in the first place - which happens in around 20% of cases. The researchers showed that these new drugs work because they target both BRAF and the growth pathways that the cells come to rely on when they become resistant.
The studies established that for both drugs, a dose of 20mg per kg per day - which when translated to humans would be achievable by taking in pill form - caused tumours to regress without significant side-effects.
The complex research involved designing and synthesising molecules shaped to overcome major drug resistance cell signalling pathways in melanoma, testing the molecules in cultures of melanoma cells and in mice, and studying of the compounds using drug-resistant tumours from patients grown in mice.
Study co-leader Professor Caroline Springer, Professor of Biological Chemistry at The Institute of Cancer Research, London, said:
"Melanomas often respond initially to the current generation of treatments, but they inevitably acquire resistance to them, and there is a desperate need for more effective options.
"Our new inhibitors are the first in a new family of drugs that attack cancers without allowing them the get-out clause of drug resistance, by blocking multiple cancer proteins at once. We are very hopeful that clinical trials from this series of new inhibitors will begin very soon - and that they will ultimately become new first or second-line options for patients who, at the moment, exhaust all the available treatments and end up with fatal disease."
Study co-leader Professor Richard Marais, Director of the Cancer Research UK Manchester Institute, based at The University of Manchester, said: "Our laboratory study showed that these new drugs deliver multiple blows to cancer by hitting several cell survival routes at once. It's a step on from the drugs that are currently available which can't multitask in this way. "The next step is testing this family of drugs in clinical trials to establish that they are both safe and effective in cancer patients, potentially providing urgently-needed new treatments for patients who have run out of options. The trial is set to open soon and we await the results with great interest."
Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said: "Malignant melanoma is the fifth most common cancer in the UK, with over 13,000 people diagnosed in 2011. Doctors already have front-line drugs to treat melanoma, but many patients gradually develop resistance to them and are left with few other treatment options. This research, which discovered how two newly developed compounds could treat drug-resistant skin cancer, may give hope to the thousands who find themselves in this situation."
###
Notes to editors
For more information contact the ICR press office on 020 7153 5380 / henry.french@icr.ac.uk. For enquiries out of hours, please call 07708 516357.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden Hospital and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk
Manchester Cancer Research Centre - http://www.mcrc.manchester.ac.uk
The Manchester Cancer Research Centre (MCRC) is a partnership founded by The University of Manchester, including the Cancer Research UK Manchester Institute, The Christie NHS Foundation Trust and Cancer Research UK. The MCRC brings together the expertise, ambition and resources of its partner organisations in the fields of cancer treatment and clinical research and provides outstanding facilities where researchers and clinicians can work closely together. The aim of the MCRC is to improve understanding of how cancer develops, in order to translate basic and clinical research into new diagnostic tests and treatments that benefit cancer patients.
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
- Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
- Today, 2 in 4 people survive cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.
Journal
Cancer Cell